使用“降低剂量强度”的PCV方案对少突胶质细胞瘤化疗:来自新加坡的经验

• 作 者: Ty A.U See S.J Rao J.P M.C. Wong 郭俊
• 机 构: National Neuroscience Institute (Singapore General Hospital Campus) Block 6 Outram Road Singapore 1
• 出 处: 世界核心医学期刊文摘(神经病学分册)
• 发表日期: 2006年11期
• 关键词: 少突胶质细胞瘤 剂量强度 中位生存时间 客观反应 甲基苄肼 环己亚硝脲 本项 通用 毒性 长春新碱

The authors propose “decreased-dose-intensity”PCV (proca-rbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86%of patients with OD and 63%with AO remain progressionfree. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.

The authors propose “decreased-dose-intensity” PCV (proca-rbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.